Tagged with HR

UAE Karim El-Alaoui Mustapha, Managing Diretor of Boehringer Ingelheim, MENA, talks about the company’s two-fold strategy in attracting, and maintaining, talent; what have been the key successes since it’s founding; and what the future aspirations are for the company. As the head of Boehringer Ingelheim (BI) in the Middle East, to…

Basic Research A round-table discussion with leading figures from Taiwan’s NHRI, covering perspectives on the current state of the Taiwanese healthcare and pharmaceutical environment, links between academia and industry, the potential of biotech to drive the Taiwanese economy in the years to come, and Taiwan’s China connection. Participants:  Hsing-Jien Kung, President, National…

ThromboGenics Dr De Haes, as the CEO of ThromboGenics for the last five years, can you provide us with an overview of the company’s main achievements that you are most proud of? At the moment, ThromboGenics basically has one key product, Ocriplasmin, which has recently completed phase-III clinical studies. Initially, this…

Boehringer Ingelheim Singapore What is the presence of Boehringer Ingelheim (BI) in Southeast Asia? In 2009, Boehringer Ingelheim decided to establish a regional operating unit for its human pharmaceutical division (prescription and OTC products) in Southeast Asia that would be managed from Singapore. This business unit was designated to oversee of all the…

Boehringer Ingelheim Austria Austria has always been a strategic market for the group: it has played a key role in Boehringer Ingelheim’s success story, as this is where the company established its first foreign subsidiary in 1948. Can you give our readers a snapshot of the strategic importance Austria has today for the…

Boehringer Ingelheim Benelux Can you illustrate to our readers the company’s main milestones and key achievements since you took the reins four years ago? In the last years we have experienced a period of strong growth for the company based on the portfolio which we had. Today, however, following a strong focus on…

UCB Phrama France Historically, UCB Pharma had a much more ‘traditional’ approach to the industry with a broader scope of operations. Recently, the company reoriented in the direction of biopharmaceuticals by moving away from chemicals and divesting from OTCs. As you have worked on the strategy and policy at headquarters in addition to…

Boehringer Ingelheim Brazil You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three years, my assignment was to open this company and to integrate it more with Brazil. We have a quite enlightened…

Boehringer Ingelheim B.V. While already having worked for Boehringer Ingelheim for quite some time, the end of 2010 marked the completion of your first full year as general manager of this Dutch affiliate. What were some of the highlights of the past year and the main lessons that you look forward to carrying…

Boehringer Ingelheim Italy The main distinctive point of Boehringer Ingelheim Italy within the group is its business structure, which relies on three different units: Boehringer Ingelheim Spa, Bidachem and Istituto de Angeli. Could you describe the role of each entity together with its contribution to resources and growth? Boehringer Ingelheim itself is responsible…

Boehringer Ingelheim Mexico You arrived to the position of Boehringer Ingelheim Mexico’s General Director in 2010, what are some of the most exciting milestones and achievements you have presided over during this time? I’ve been in the company for 18 years, and came back from Germany in 2010 to become the company’s first…

Boehringer Ingelheim Chile What have been Boehringer Ingelheim’s major milestones and achievements since your establishment in Chile? Chile, in the regional context, represents a very important market with a solid evolution in terms of sales. For our company, on a regional scale, the country has been growing above the average rate of 15.6%…